**FOOD AND DRUG ADMINISTRATION (FDA)**  
**Center for Biologics Evaluation and Research (CBER)**  
**165th Meeting of the Vaccines and Related Biological Products Advisory Committee**  
**Silver Spring, MD**  
**March 5, 2021**  
**AGENDA**

**Topic:** The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 – 2022 influenza season.

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00am – 9:10am</td>
<td><strong>Opening Remarks: Call to Order, Introduction of Committee</strong> Hana El Sahly, M.D., Chair, VRBPAC</td>
</tr>
<tr>
<td></td>
<td><strong>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement</strong> Kathleen Hayes, M.P.H. Designated Federal Officer, VRBPAC CBER, FDA</td>
</tr>
<tr>
<td>9:10am – 9:30am</td>
<td><strong>Introduction</strong> Jerry Weir, Ph.D. Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA Q &amp;A: 5 min</td>
</tr>
<tr>
<td>9:30am – 9:45am</td>
<td><strong>U.S. Surveillance</strong> Lisa Grohskopf, M.D., M.P.H. CAPT USPHS Associate Chief for Policy &amp; Liaison Activities, Epidemiology &amp; Prevention Branch, Influenza Division Centers for Disease Control and Prevention (CDC) Q &amp;A: 5 min</td>
</tr>
<tr>
<td>9:45am – 10:10am</td>
<td><strong>Global Influenza Virus Surveillance and Characterization</strong> David Wentworth, Ph.D. Branch Chief Influenza Division Virology, Surveillance, and Diagnostic Branch Centers for Disease Control and Prevention (CDC) Q &amp;A: 10 min</td>
</tr>
</tbody>
</table>
# Agenda

**11:20am – 11:30am** | **Break**  
**11:30am – 11:55am** | **DoD Vaccine Effectiveness Report**  
LTC Kevin Taylor, M.D., MTM&H  
Focus Area Chief  
Global Emerging Infections Surveillance Branch  
Armed Forces Health Surveillance Division  
Public Health Division - DHA  
Kathleen Creppage, DrPh., M.P.H  
Senior Epidemiologist  
Armed Forces Health Surveillance Division  
Global Emerging Infections Surveillance Branch  
Q & A: 5 min  
**11:55am – 12:20pm** | **Candidate Vaccine Strains & Potency Reagents**  
Manju Joshi, Ph.D.  
Lead Biologist  
Division of Biological Standards & Quality  
Office of Compliance and Biologics Quality  
CBER/FDA  
Q & A: 5 min  
**12:20pm – 12:45pm** | **Comments from Manufacturer Representative**  
Lauren Parker, Ph.D.  
AstraZeneca  
Q & A: 5 min  
**12:45pm – 1:30pm** | **Lunch** (45 min.)  
**1:30pm – 2:30pm** | **Open Public Hearing** (60 min.)  
**2:30pm – 3:30pm** | **Committee Discussion, Recommendations, and Vote**  
**3:30 pm** | **Adjourn Meeting**